Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Friday, October 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. has announced that two posters on the long-term survival data of botensilimab (BOT) in combination with balstilimab (BAL) will be presented at the SITC 2026 Annual Meeting. The meeting is scheduled for November 4-8, 2026, in Phoenix, Arizona. This presentation underscores Agenus's commitment to advancing immuno-oncology research.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agenus is presenting promising long-term survival data.
  • Research focuses on innovative immuno-oncology treatments.
  • The event highlights the company's leadership in the field.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
3.1%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Botensilimab
Phase 2 · Colorectal Cancer

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona. The clinical poster will review the featur

Frequently Asked Questions

What data will Agenus present at SITC 2026?

Agenus will present long-term survival data for botensilimab (BOT) combined with balstilimab (BAL).

When is the SITC 2026 Annual Meeting?

The SITC 2026 Annual Meeting will take place from November 4-8, 2026.

Where will the SITC 2026 meeting be held?

The SITC 2026 meeting will be held in Phoenix, Arizona.

What is botensilimab?

Botensilimab (BOT) is an Fc-enhanced multifunctional anti-CTLA-4 antibody.

What is balstilimab?

Balstilimab (BAL) is an anti-PD-1 antibody used in cancer treatment.

ShareAdd on Google
Tags: AGEN Agenus BOT BAL SITC 2026 immuno-oncology
Last updated: Oct 2, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
BotensilimabPhase 2
Colorectal Cancer →

Catalyst track record

+121%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →